Moreover, it was recently reported that neoadjuvant therapy using anti-PD-1/PD-L1 therapy and irradiation is associated with a favorable pathological response such as pathological CR and PR in patients with locally advanced rectal cancer, locally advanced head and neck squamous cell carcinoma, and early-stage NSCLC14–16. The gene discussed is PDCD1; the disease is rectal cancer.